Fierce Pharma
FEBRUARY 5, 2024
After leading Novartis and Roche through pivotal years in 2023, the CEOs of the Swiss drug giants each netted multimillion-dollar compensation packages. | After leading Swiss drug giants Novartis and Roche through pivotal years, their CEOs have each netted multimillion-dollar compensation packages for 2023.
MedCity News
FEBRUARY 5, 2024
This year, industry experts think that some digital health startups will have to confront their challenges more head-on than they did in 2023. Some companies may need to do things like fundraise at a lower valuation, explore opportunities for an acquisition or exit or, in some cases, consider the possibility of shutting down operations.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
FEBRUARY 5, 2024
If a new package of pivotal data satisfies the FDA, GSK could have another run at the U.S. | If a new package of pivotal data satisfies the FDA, GSK could have another run at the U.S. multiple myeloma market with its previously withdrawn BMCA-targeted antibody-drug conjugate, Blenrep.
MedCity News
FEBRUARY 5, 2024
The only way to effectively scale care coordination to meet the needs of digital consumers is through technology, combined with empowered staff and transformed processes.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
FEBRUARY 5, 2024
Less than two months after the FDA approved the combination treatment of Astellas and Pfizer’s Padcev and Merck’s Keytruda in first-line bladder cancer, the Japanese company has
MedCity News
FEBRUARY 5, 2024
After Novo Holdings acquires Catalent, it will sell three of the contract manufacturing giant’s sites to Novo Nordisk. Those facilities already make Novo Nordisk’s GLP-1 drugs for metabolic conditions, and they will help the company meet projected demand for these products in years to come.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
PharmaTimes
FEBRUARY 5, 2024
The aggressive brain cancer is responsible for over 3,000 cases in the UK every year
Fierce Pharma
FEBRUARY 5, 2024
As new legislation stands to threaten the U.S. business of certain Chinese biopharma companies, CDMO giant WuXi AppTec has stepped in to make a case for itself. | The company's executives inked an open letter after the recent BIOSECURE act flagged WuXi AppTec and other Chinese drugmakers as potential national security threats.
MedCity News
FEBRUARY 5, 2024
Virtual nursing, a concept that marries the strengths of traditional nursing models – primary nursing and team nursing – is emerging as a promising solution to address the challenges faced by healthcare organizations.
Fierce Pharma
FEBRUARY 5, 2024
After Novartis reportedly backed out of late-stage talks to acquire Cytoki | The company has a leading bid for the cancer drug maker over Incyte, Reuters reports, citing two people familiar with the matter.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
MedCity News
FEBRUARY 5, 2024
Several recent developments signal increased support for psychological assessments and treatments.
Fierce Pharma
FEBRUARY 5, 2024
By Matthew Cotter, PhD, Vice President, Global Medical Affairs, Prostate Cancer, Pfizer Oncology Sponsored by Pfizer Inc. | Ongoing scientific research is needed to better understand prostate cancer and identify treatment options to help address unmet needs of patients.
pharmaphorum
FEBRUARY 5, 2024
A bladder cancer study prompts Astellas to lift peak sales prediction for Padcev, although its menopause therapy Veozah isn’t ramping up as hoped.
MedCity News
FEBRUARY 5, 2024
Employers have been making major investments in healthcare for their employees. Yet, many disparities still exist, particularly when it comes to access and outcomes, according to a recent report from Morgan Health.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
pharmaphorum
FEBRUARY 5, 2024
Better-than-expected sales of some of its new products, including Skyrizi and Rinvoq, helped AbbVie handle a sharp decline in sales of former cash-cow product Humira in the last quarter of 2023.
MedCity News
FEBRUARY 5, 2024
Based on the risk profiles of orthopaedic operations, a shoulder replacement is actually safer than that of a hip or knee and therefore an ideal candidate for the ambulatory surgical center environment.
pharmaphorum
FEBRUARY 5, 2024
4D Molecular Therapeutics' 4D-150 gene therapy for wet AMD has shown efficacy and a reduced need for eye injections with current therapy Eylea in a phase 2 trial.
PharmaTimes
FEBRUARY 5, 2024
The neurodegenerative condition currently affects over 944,000 people in the UK
pharmaphorum
FEBRUARY 5, 2024
Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes and obesity drugs. The deal includes $11 billion upfront to buy the fill-finish sites that Novo Nordisk said will enable “an expansion of the manufacturing capacity at scale and speed while providing future optionality and flexibility for Novo Nordisk’s existing supply network.
MedCity News
FEBRUARY 5, 2024
Health aid from the private US healthcare community to Ukraine is stalling. To re-engage and do more we should take a bottom-up and people-centric approach to aid and focus on long term needs.
European Pharmaceutical Review
FEBRUARY 5, 2024
Novo Nordisk is set to acquire three fill-finish manufacturing sites from Novo Holdings A/S (Novo Holdings) for $11 billion. This agreement is part of a transaction in which Novo Holdings agreed to acquire the contract development and manufacturing organisation (CDMO) Catalent. The three manufacturing sites in Anagni in Italy, Brussels in Belgium and in Bloomington, Indiana in the US, specialise in the sterile filling of drugs.
pharmaphorum
FEBRUARY 5, 2024
The 38th PM Society Awards will take place on Friday 15th March in London, with Twist Health as the headline sponsor. It is the longest running and largest awards event in the pharma marketing and healthcare agency calendar. To view all the finalist agencies and clients, please visit the PM Society’s website.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
European Pharmaceutical Review
FEBRUARY 5, 2024
Incentivising small molecule drug innovation According to the Biotechnology Innovation Organization (BIO), the bipartisan Ensuring Pathways to Innovative Cures ( EPIC Act ) passed last week in the US, is a “critical” step for incentivising small molecule drug innovation. Representative Congressman Dr Greg Murphy, alongside Don Davis and Brett Guthrie, introduced the US legislation to fix the “pill penalty”, BIO confirmed.
pharmaphorum
FEBRUARY 5, 2024
The first patient has been treated in a phase 1/2 trial of a Moderna cancer vaccine designed to generate antibodies against immune checkpoints PD-L1 and IDO1
Pharmaceutical Technology
FEBRUARY 5, 2024
Regeneron Pharmaceuticals' application for linvoseltamab has received acceptance from the EMA for review to treat multiple myeloma.
PharmaVoice
FEBRUARY 5, 2024
The biotech’s bone- and muscle-building treatments could someday help humans reach other planets.
Pharmaceutical Technology
FEBRUARY 5, 2024
V-116 is a conjugate vaccine commercialized by Merck, with a leading Pre-Registration program in Streptococcal Pneumonia.
Pharmaceutical Commerce
FEBRUARY 5, 2024
An analysis of the two main new models for pharmacy—unique direct—to-consumer for brands and cash pay for generics—and what members of industry think about them.
Pharmaceutical Technology
FEBRUARY 5, 2024
Tozorakimab is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Chronic Obstructive Pulmonary Disease (COPD).
Pharmacy Times
FEBRUARY 5, 2024
This approach may help prevent premature deaths attributed to preventable or treatable cardiovascular disease.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
306 
Let's personalize your content